Two of our grantees illustrate distinct and shared ways that the pandemic has disrupted biomedical research and affected the scientific community.
In July 2021, our Symposium convened online, allowing more people than ever to participate and hear from experts working across disciplines.
The Foundation made an early Program Related Investment to support Thetis Pharmaceuticals development of a novel therapy for ulcerative colitis, which just reached a new regulatory milestone.
Prominent journals featured cutting-edge advances by five grantees whose research focuses diagnostics, new therapies and biomarkers of mucosal healing that serve patients directly.
We’ve begun a journey of inquiry into the role that the Rainin Foundation can play to address racial disparities in the biomedical enterprise.
With her lab at Harvard Medical School and Massachusetts General Hospital, Dr. Kate Jeffrey has embarked on a new frontier to research the human virome.
Dr. Gwendalyn Randolph’s cutting-edge instincts led to a novel technique that makes human tissue look like glass, and she combined this with advanced 3-D imaging to peer more deeply into the workings of Crohn’s disease.
